Introduction {#s1}
============

Chronic obstructive pulmonary disease (COPD) is a common and preventable illness that carries a significant economic and social burden. Current economic data shows that in the United States, COPD is the responsible for approximately \$52 billion in direct and indirect healthcare costs \[[@R01]\]. The Burden of Obstructive Lung Disease (BOLD) program and other large epidemiologic studies approximate that 384 million individuals are affected, estimating a global prevalence of 11.7% \[[@R02]\]. However, COPD remains largely underdiagnosed, likely due to differences in diagnostic criteria and patient presentation \[[@R03]\]. Currently, it is the fourth leading cause of death worldwide, with an estimated 3 million deaths annually \[[@R04], [@R05]\]. Epidemiologic trends have estimated that COPD will climb to third by the year 2020, thereby claiming approximately 4.5 million deaths annually \[[@R06], [@R07]\]. This increase in prevalence is attributable to the aging population and the increased incidence of smoking worldwide \[[@R06]\].

COPD is a disease characterized by incompletely reversible airway obstruction \[[@R08]\]. It is further defined as the combination of small airway disease and parenchymal destruction that leads to the hallmark airflow limitation. Exposure to noxious particles and gases causes chronic airway inflammation, resulting in airway remodeling. Chronic lung injury and subsequent repair leads to structural lung changes, such as airway narrowing, wall thickening, and loss of alveolar attachments, thus causing decreased lung elasticity and the parenchymal destruction that is pathologically consistent with emphysema \[[@R9]\]. These structural lung changes also result in the chronic respiratory symptoms associated with COPD, including dyspnea, wheezing, chest tightness, and cough with or without sputum production.

The most common risk factor for COPD remains smoking; however, studies show that this is an association rather than a causal relationship \[[@R9]\]. Cigarette smoking is associated with a higher prevalence of pulmonary symptoms, a greater reduction in the forced expiratory volume in the first second (FEV1) and a greater mortality in patients with COPD \[[@R10]\]. Another significant risk factor for the development of COPD is a history of asthma. A long-term longitudinal study of patients with asthma found that 20% of the studied asthmatics developed irreversible airflow obstruction, while another report found that asthmatics had a 12-fold higher risk of developing COPD compared to non-asthmatics \[[@R11], [@R12]\]. Occupational exposures also play a role in the development of COPD. A large-scale National Health and Nutrition Examination Survey estimated that the fraction of COPD attributable to workplace exposure was 19.2% in smokers and 31.1% in nonsmokers \[[@R13]\]. Other risk factors include age, genetics, socioeconomic status, and lung growth and development. Previously, it used to be believed that males were predisposed to developing COPD, but recent studies have shown an almost even gender distribution \[[@R14]\].

The airflow limitation that is the hallmark of COPD can be diagnosed via pulmonary function tests (PFTs) in patients who present with symptoms and risk factors concerning for the disease. PFTs are a reproducible and objective measurement of airflow obstruction. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines of 2017 define COPD as the ratio of the forced expiratory volume in one second and the forced vital capacity (FEV1/FVC) \< 0.7 post-bronchodilator administration \[[@R9]\]. They further characterize the severity of the disease by the reduction in FEV1. The modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) are then commonly used to assess the severity of a patient's symptoms. These three tests, along with exacerbation risk, are used in the GOLD guidelines to classify patients in one of the four stages that guide the optimal treatment. The GOLD 2017 guidelines also provide specific algorithms for the treatment of each stage and the modifications that can be made if patients' symptoms are poorly controlled.

Although the GOLD guidelines are considered a comprehensive review of the literature available for the diagnosis and management of COPD, adherence to the criteria varies among practitioners. One cross sectional survey evaluating the management of more than 1,500 COPD patients in multiple countries found that adherence to the GOLD 2014 criteria varied across the GOLD stages, with the lowest rates being seen in stage B patients \[[@R15]\]. In the same study, the investigators also found that, in general, the vast majority of patients reported a high symptom burden, thus suggesting misalignment of practicing with GOLD recommendations \[[@R15]\]. Another report looking at prescribing practices over a 5-year period found that medications prescribed to COPD patients correlated not with the GOLD treatment guidelines, but instead with the number of health care visits \[[@R16]\].

Although these studies describe prescribing tendencies, they pertain to previous iterations of the GOLD guidelines. Very little data has been published describing whether adherence to the GOLD guidelines has improved with the 2017 updates. Many COPD patients have significant disease burden; however, there is yet to be a clear correlation between misalignment with GOLD practicing guidelines and increased patient morbidity and mortality. We designed this study to examine the outpatient management of COPD while paying special attention to whether or not adherence to the 2017 GOLD guidelines affected patient outcomes.

Materials and Methods {#s2}
=====================

Study selection {#s2a}
---------------

This study was a retrospective electronic medical record review that observed the outpatient management of patients with COPD. Patients were seen in a single suburban primary care office between January 1, 2017 and December 31, 2017. The inclusion criteria were patients aged 18 and older who presented to the office during the time period with a documented diagnosis of COPD in the electronic medical record. The exclusion criteria were patients under the age of 18 years, who had no diagnosis of COPD, or who had another pulmonary disorder(s). This study was reviewed and approved by the Institutional Review Board at Cooper University Hospital and was conducted in compliance with all the applicable ethical standards of the institution.

Data collection {#s2b}
---------------

The following data were collected for each patient: age, gender (male or female), race (Caucasian, African American, Asian, or Other), body mass index, history of cigarette smoking, documented diagnosis of COPD or emphysema, spirometry confirming diagnosis of COPD, FEV1, FEV1/FVC ratio, carbon monoxide diffusion capacity (DLCO), outpatient pulmonary follow-up, and comorbid medical conditions, such as atherosclerotic cardiovascular disease, hypertension, hyperlipidemia, diabetes mellitus, allergic and immunological disorders, malignancy, immunodeficiency, thyroid conditions, gastrointestinal disorder, polycythemia, other hematological illnesses, central nervous system disorders, obstructive sleep apnea and chronic kidney disease stage 3 to 5. Additional data included the number of exacerbations and hospitalizations in the preceding year, COPD assessment test score, Modified Medical Research Council dyspnea score, medication management (short acting beta agonist (SABA), long acting beta agonist (LABA), short acting antimuscarinic agent (SAMA), long acting antimuscarinic agent (LAMA), inhaled corticosteroid (ICS), roflumilast, oral corticosteroid, home oxygen therapy, and oral antibiotic), use of home oxygen therapy, pulmonary rehabilitation, GOLD management category, adherence to GOLD recommendations and mortality.

Statistical analysis {#s2c}
--------------------

Data were collected and entered into a Microsoft Excel spreadsheet (2016, Redmond, Washington, USA). Statistical analysis was carried out using SPSS software (IBM Corporation, Armonk, New York, USA). Categorical data were analyzed as frequencies with percentages and continuous data were analyzed as means with standard deviations. Frequencies were compared using Chi-square and Fisher's exact tests. Logistic regression models were used to determine if the variables had a significant relationship with mortality, number of exacerbations per year and disease progression. A P value \< 0.05 was used to determine statistical significance.

Results {#s3}
=======

A total of 158 patients were included in this study. The mean age of patients was 71.58 ± 12.9. The majority of the patients were female (55.7%) ([Table 1](#T1){ref-type="table"}). The mean body mass index of the patients was 27.61 ± 6.67 kg/m^2^. The majority of patients were white (77.2%), followed by black (13.3%), Asian (5.1%) and Hispanic (4.4%). The majority (96.2%) of the patients had a history of smoking and 94.9% had a documented diagnosis of COPD at time of presentation. On the other hand, only two-thirds (65.2%) of patients had evidence of emphysema on radiography. Of the 158 patients in this study, 56.3% of patients had spirometric confirmation of the diagnosis, and 55.7% had pulmonary follow-up. The patients who had pulmonary follow-up were more likely to have documentation of spirometric diagnosis of COPD compared to the patients who did not have pulmonary follow-up (78.4% vs. 25.7%; P \< 0.001). We were able to classify patients according to the GOLD guidelines in 56.3% of the patients. Thirty-six percent of these patients were treated based on the GOLD guidelines while 64% were not.

###### Demographic and Clinical Characteristics

  Variable                               Frequency (n = 158)
  -------------------------------------- ---------------------
  Age (years, mean (SD))                 71.58 (12.9)
  Body mass index (kg/m^2^, mean (SD))   27.61 (6.67)
  Gender                                 
    Male, n (%)                          70 (44.3)
    Female, n (%)                        88 (55.7)
  Race                                   
    White, n (%)                         122 (77.2)
    Black, n (%)                         21 (13.3)
    Asian, n (%)                         8 (5.1)
    Hispanic, n (%)                      7 (4.4)
  Social                                 
    Smoking (n, %)                       152 (96.2)
  Diagnosis                              
    COPD (n, %)                          150 (94.9)
    Emphysema (n, %)                     103 (65.2)
    Pulmonary follow-up (n, %)           88 (55.7)
  Spirometric diagnosis                  
    COPD (n, %)                          89 (56.3)
    Pulmonary follow-up (n, %)           69 (78.4)
    No pulmonary follow-up (n, %)        20 (21.6)
    GOLD criteria calculated (n, %)      89 (56.3)
    Management per GOLD (n, %)           32 (36.0)
    Management not per GOLD (n, %)       57 (64.0)

SD: standard deviation; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Obstructive Lung Disease.

The majority of patients in our study were treated with SABA (90.5%), followed by LABA (56.3%) and ICS (54.4%) ([Table 2](#T2){ref-type="table"}). A LAMA was prescribed to about two-fifths of the patients (41.1%). About a quarter (24.1%) of the patients were on home oxygen therapy. Only 11.4% of patients were referred to pulmonary rehabilitation. For those patients treated according to the GOLD guidelines, 87.5% received SABA, 50.0% received LAMA, 46.9% received LABA, 25.0% received ICS and 25.0% were on home oxygen therapy. For those patients who were not treated according to the GOLD guidelines, 96.5% received SABA, 73.7% received ICS, 70.2% received LABA, 49.1% received LAMA, and 33.3% were on home oxygen therapy. More patients received LABA and ICS therapy in the group who were not treated according to the GOLD guidelines compared to the patients who were treated according to the GOLD guidelines. These therapeutic differences were statistically significant in regards to LABA (P \< 0.05) and ICS therapy (P \< 0.001). The differences in the use of other pharmacologic and non-pharmacologic therapies were not statistically significant between the two groups.

###### Management of COPD

  Variable                          All frequency (n = 158)   GOLD frequency (n = 32)   No GOLD frequency (n = 57)   P value (GOLD vs. No GOLD)
  --------------------------------- ------------------------- ------------------------- ---------------------------- ----------------------------
  SABA (n, %)                       143 (90.5)                28 (87.5)                 55 (96.5)                    0.183
  LABA (n, %)                       89 (56.3)                 15 (46.9)                 40 (70.2)                    \< 0.05
  SAMA (n, %)                       12 (7.6)                  4 (12.5)                  3 (5.3)                      0.246
  LAMA (n, %)                       65 (41.1)                 16 (50.0)                 28 (49.1)                    0.937
  ICS (n, %)                        86 (54.4)                 8 (25.0)                  42 (73.7)                    \< 0.001
  Roflumilast (n, %)                1 (0.6)                   0 (0)                     1 (1.8)                      1.000
  Home oxygen therapy (n, %)        38 (24.1)                 8 (25.0)                  19 (33.3)                    0.412
  Pulmonary rehabilitation (n, %)   18 (11.4)                 9 (28.1)                  7 (12.3)                     0.062

SABA: short acting beta agonist; LABA: long acting beta agonist; SAMA: short acting antimuscarinic agent; LAMA: long acting antimuscarinic agent; ICS: inhaled corticosteroid.

The mortality rate was 9.5% among all the patients in our study. Patients treated according to the GOLD guidelines had a mortality rate of 12.5%, while those not treated according to the GOLD guidelines had a mortality rate of 12.3% ([Table 3](#T3){ref-type="table"}). There was no statistically significant difference in mortality between the two groups. About half of all the patients (48.7%) required oral corticosteroids during the 1-year period and 46.2% required oral antibiotics. Although a higher number of patients who were not treated according to the GOLD guidelines required oral corticosteroids during the 1-year period (64.9%) compared to the 43.8% of patients treated according to the GOLD guidelines, the difference was not statistically significant (P = 0.053). Half of the patients treated according to the GOLD guidelines (50%) received oral antibiotics compared to 56.1% patients who were not treated according to the GOLD guidelines. The difference was not statistically significant. The patients who were not treated according to the GOLD guidelines had a larger distribution of exacerbations compared to the patients treated according to the GOLD guidelines ([Fig. 1](#F1){ref-type="fig"}), but the outcome data were not statistically significant (P = 0.082).

###### Patient Outcomes

  Variable                All frequency (n = 158)   GOLD frequency (n = 32)   No GOLD frequency (n = 57)   P value (GOLD vs. No GOLD)
  ----------------------- ------------------------- ------------------------- ---------------------------- ----------------------------
  Oral corticosteroid     77 (48.7)                 14 (43.8)                 37 (64.9)                    0.053
  Oral antibiotic         73 (46.2)                 16 (50.0)                 32 (56.1)                    0.577
  Increase in home O~2~   16 (10.1)                 6 (18.8)                  7 (12.3)                     0.407
  Mortality               15 (9.5)                  4 (12.5)                  7 (12.3)                     1.000

![Comparison of the distribution of exacerbations for patients treated according to the GOLD guidelines (n = 32) versus those who were not (n = 57). GOLD-adherent patients had outliers in their distribution of exacerbations. The star represents one subject who experienced six exacerbations during the 1-year period. The asterisk represents two subjects who experienced five exacerbations. The circle represents one subject who experienced three exacerbations.](jocmr-11-556-g001){#F1}

Discussion {#s4}
==========

COPD carries significant social and economic burden. Epidemiologic studies have shown that the incidence and mortality of COPD are increasing \[[@R04]-[@R07]\]. While much of this is due to the aging population and the increased incidence of smoking worldwide, new guidelines are routinely published to assist in the management of COPD in the hopes of preventing a similar trend in morbidity and mortality. The GOLD guidelines were updated in 2017 to provide a more comprehensive blueprint for the diagnosis and management of COPD. While it is considered the standard of care, the adherence to the previous iterations of these guidelines varies greatly among healthcare practitioners \[[@R15], [@R16]\].

In our study, approximately one-third (36%) of the patients staged according to the GOLD criteria received therapy according to the GOLD guidelines, which falls in line with the previous iterations of the GOLD guidelines \[[@R17]-[@R21]\]. Nonadherence to the GOLD prescribing guidelines likely occurs for a variety of reasons. An important initial consideration is the low physician awareness of evolving guidelines and the associated gaps in knowledge regarding the diagnosis and treatment of COPD \[[@R22]\]. One cross sectional study found that, in their cohort, only approximately one-third of physicians knew the GOLD criteria \[[@R23]\]. Along the same lines, Li and associates demonstrated that approximately 55% of general practitioners recognized the GOLD criteria, yet only 8% of patients received therapy in accordance with the GOLD guidelines \[[@R24]\]. It is important to also mention that a survey of primary care physicians in New York reported that low self-efficacy and physician time constraints played a major role in GOLD nonadherence \[[@R25]\]. Current literature does not prove that lack of perceived benefit or disagreement with the guidelines are potential barriers to adherence to the GOLD criteria. While there are physician-related barriers to GOLD adherence, there are also patient-related factors to mention as well. Symptomatology and exacerbation rates, as opposed to objective spirometric criteria, are significant drivers of patient management \[[@R17], [@R26]\].

Our cohort demonstrated no significant difference in patient outcomes when comparing GOLD-adherent versus GOLD non-adherent management. A potential explanation for this may be that, as mentioned above, prescribers advance COPD therapy based on symptoms, functional status and exacerbation risk, as opposed to spirometric data. Therefore, patients may be overtreated, especially in light of growing evidence that the use of triple therapy may result in lower exacerbation risk, fewer hospitalizations, improved lung function and better quality of life \[[@R27], [@R28]\].

The available literature studying the effects of GOLD adherence offers conflicting data, although little is currently known in regards to the 2017 guidelines. In a large-scale study, Mannino and associates found that patients treated according to the 2011 GOLD guidelines had a benefit in nearly all outcomes, including COPD-related symptoms, emergency department visits and hospitalizations \[[@R17]\]. Conversely, Jochmann and associates found that guideline adherence did not significantly affect exacerbation rates, symptoms, or lung function decline \[[@R29]\]. While outcomes may vary between cohorts, longer term studies are needed to truly ascertain the true effect of adherence to the GOLD guidelines.

Interestingly, our study found that there was a significant difference in the use of ICS when comparing GOLD adherent versus GOLD non-adherent management (P \< 0.001). The GOLD non-adherent patients were three times more likely to be prescribed an ICS. Current guidelines state that an ICS should be added to regular bronchodilator therapy in COPD patients with severe airflow limitation and/or frequent exacerbations \[[@R30]\]. Despite these guidelines, Izquierdo and associates found that ICS are widely prescribed to all stages of COPD patients \[[@R31]\]. The overuse of ICS may be due to practitioners starting patients on ICS/LABA or triple therapy to cover both asthma and COPD, as there is often a lack of spirometry differentiating the two diagnoses \[[@R32]\].

In our cohort, 56.3% of patients were diagnosed with COPD using spirometry. We demonstrate a higher use of spirometry when compared to the existing literature, although much improvement is still to be made. Two large retrospective studies demonstrated that spirometry was only used for approximately one-third of newly diagnosed COPD patients \[[@R33], [@R34]\]. Another study showed that only 32% of their cohort had spirometric diagnosis of COPD, but expanded further by stating that the use of testing decreased with increasing age \[[@R35]\]. The likely explanation for the low usage of spirometry is that many patients come to primary care practices with a documented diagnosis of COPD without spirometric confirmation and physicians then conclude the patients' COPD diagnoses based on their clinical examination and the patients' history of smoking. It is unclear whether lack of knowledge regarding, or the attitude towards the utility of, spirometry affects clinician use \[[@R34]\]. Despite spirometry being the gold standard tool to establish the diagnosis and the degree of airflow limitation, the variability in its use makes us vulnerable to misdiagnosis and inappropriate treatment \[[@R36]\].

Unsurprisingly, patients who followed with a pulmonologist were approximately four times more likely to have spirometric diagnosis of COPD (P \< 0.001). This is consistent with previous studies, one of which demonstrated that use of spirometry was 3.3 times higher for patients following with pulmonologists \[[@R34]\]. It is currently unclear exactly why this is the case, but this finding likely underscores the importance of referring potential COPD patients to pulmonologists for further workup and management.

Based on our literature review, there is little data analyzing adherence to the 2017 iteration of the GOLD guidelines and its effect on patient outcomes. Therefore, to the best of our knowledge, our study is the first to take an in-depth look into the adherence of the 2017 GOLD guidelines and its effect on outcomes.

The major strength of our study was establishing a strictly narrow range of inclusion criteria so as to exclude patients with potential confounding comorbidities that might have impacted outcomes of their COPD management.

There were several limitations to our study that need to be mentioned. This retrospective electronic medical record review was limited to a single outpatient suburban primary care office, therefore limiting its generalizability. Our study period lasted for 12 months, thus limiting our ability to draw conclusions regarding long-term COPD care. Similarly, limitation of documentation of confounding factors in the electronic medical records, such as socioeconomic status, insurance status, living situation, etc., limited our ability to analyze the influence of such factors in patient outcomes.

We conclude that adherence to the 2017 GOLD guidelines had no statistically significant difference in patient outcomes. However, GOLD non-adherent patients received LABA and ICS therapy at a significantly higher frequency compared to GOLD-adherent patients. Further studies are needed examining long-term practicing guidelines at multiple institutions nationwide.
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